<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892022000300007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[¿Es importante conocer el tipo de transcripto BCR-ABL en la leucemia mieloide crónica?]]></article-title>
<article-title xml:lang="en"><![CDATA[Is it important to know the type of BCR-ABL transcript in chronic myeloid leukemia?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amor Vigil]]></surname>
<given-names><![CDATA[Ana María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Alonso]]></surname>
<given-names><![CDATA[Carmen Alina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández Martínez]]></surname>
<given-names><![CDATA[Lesbia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>38</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892022000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892022000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892022000300007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La leucemia mieloide crónica se caracteriza por la ocurrencia de una translocación recíproca entre los cromosomas 9 y 22; que da origen a un cromosoma 22 derivativo conocido como Filadelfia. En el sitio de unión se forma el gen de fusión BCR-ABL que conlleva a la síntesis de una proteína híbridacon propiedades oncogénicas. El sitio de unión entre los cromosomas 9 y 22 es variable y da lugar a transcritos diferentes; los conocidos como e13a2 y e14a2 son los más frecuentes y estudiados. El análisis de las características clínico-hematológicas de presentación y la respuesta al tratamiento entre los pacientes portadores de e13a2 o e14a2 ha revelado diferencias que pueden ser útiles para la predicción del pronóstico. Se realizó una revisión de la literatura científica a través de PUBMED. Se analizó y resumió la información. Se evidencian diferentes características de presentación, pero no existe coincidencia entre todos los autores. Respecto al comportamiento de la respuesta al tratamiento con inhibidores de tirosina quinasa, algunos autores encuentran diferencias y algunos sugieren que puede tratarse de dos enfermedades diferentes. Puede ser importante conocer el tipo de transcripto BCR-ABL en la LMC ya que, al menos entre los dos más frecuentes, existen diferencias que pueden ser útiles en la predicción del pronóstico para el paciente, así como para el manejo del tratamiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Chronic myeloid leukemia is characterized by the occurrence of a reciprocal translocation between chromosomes 9 and 22; which gives rise to a derivative chromosome 22 known as Philadelphia. At the binding site, the BCR-ABL fusion gene is formed, which leads to the synthesis of a hybrid protein with oncogenic properties. The binding site between chromosomes 9 and 22 is variable and gives rise to different transcripts; those known as e13a2 and e14a2 are the most frequent and studied. The analysis of the clinical-hematological characteristics of presentation and the response to treatment among patients with e13a2 or e14a2 has revealed differences that may be useful for the prediction of prognosis. To describe the different characteristics reported for one or another transcript and to know if it is important to know the type of transcript in the CML. A review of the scientific literature was carried out through PUBMED. The information was analyzed and summarized. Different presentation characteristics are evident but there is no coincidence between all the authors. Regarding the behavior of the response to treatment with tyrosine kinase inhibitors, some authors find differences and some suggest that it may be two different entities. It may be important to know the type of BCR-ABL transcript in CML cause, at least between the two most frequent, there are differences that may be useful in predicting the prognosis for the patient as well as for the management of treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[transcripto BCR-ABL]]></kwd>
<kwd lng="es"><![CDATA[leucemia mieloide crónica]]></kwd>
<kwd lng="es"><![CDATA[cromosoma Filadelfia]]></kwd>
<kwd lng="en"><![CDATA[BCR-ABL transcripts]]></kwd>
<kwd lng="en"><![CDATA[chronic myeloid leukemia]]></kwd>
<kwd lng="en"><![CDATA[Philadelphia chromosome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabbour]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kantarjian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic myeloid leukemia 2020 update on diagnosis, therapyand monitoring]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2020</year>
<volume>95</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>691-709</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iacoboni]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Plunkett]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kantarjian]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Estey]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Keating]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mc Credie]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-dose cytosine arabinoside treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J. Clin]]></article-title>
<source><![CDATA[Oncol]]></source>
<year>1986</year>
<volume>4</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1079-88</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype]]></article-title>
<source><![CDATA[Blood]]></source>
<year>1996</year>
<volume>88</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2375-84</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chereda]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The biology and pathogenesis of chronic myeloid leukemia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Hehlmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Chronic myeloid leukemia]]></source>
<year>2016</year>
<page-range>17-40</page-range><publisher-loc><![CDATA[Switzerland ]]></publisher-loc>
<publisher-name><![CDATA[Springer International Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greenfield]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[McMullan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Robson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McGimpsey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Catherwood]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McMullin]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia]]></article-title>
<source><![CDATA[BMC Hematol]]></source>
<year>2019</year>
<volume>19</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molica]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abruzzese]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Breccia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia]]></article-title>
<source><![CDATA[Mediterr J Hematol Infect Dis]]></source>
<year>2020</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia]]></article-title>
<source><![CDATA[Open Med]]></source>
<year>2021</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>904-12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castagnetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gugliotta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Breccia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iurlo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Levato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Albano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2017</year>
<volume>92</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>797-805</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D'Adda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Farina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schieppati]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Borlenghi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bottelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cerqui]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The e13a2 BCR-ABL Transcript Negatively Affects Sustained Deep Molecular Response and the Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Receive Tyrosine Kinase Inhibitors]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2019</year>
<volume>125</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1674-82</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baccarani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castagnetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gugliotta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rosti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Soverini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Albeer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The proportion of different BCR-ABL1 transcript types in chronicmyeloid leukemia An international overview]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2019</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1173-83</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Almeida Filho]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Maia Filho]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Cavalcante Barbosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alves Dutra]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[de Castro]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Barroso Duarte]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does BCR-ABL transcript type in?uence the prognosis of patients in chronic myelogenous leukemia chronic phase?]]></article-title>
<source><![CDATA[Hematol Transfus Cell Ther]]></source>
<year>2019</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>114-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amor-Vigil]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[González-Medina]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cayado-Gutiérrez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Antuña]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frecuencia de los transcriptos BCR-ABL en pacientes cubanos con leucemia mieloide crónica]]></article-title>
<source><![CDATA[Rev Cubana Hematol Immunol Hemoter]]></source>
<year>2012</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kantarjian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shamanna]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Daver]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Sasaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2016</year>
<volume>127</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1269-75</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
